Any current/future new fundraising through debt or equity?

Current expansions have been mostly funded through internal sources; out of Rs. 78 crore invested in three companies, only Rs. 1 crore has been utilized out of a Rs. 2 crore loan. The company aims to avoid taking substantial new loans and has enough reserves for planned expansions. Future CAPEX for injectable line expansion (estimated Rs. 30-35 crore) will be met without major debt, maintaining the company’s current financial status. No explicit mention of planned equity fundraising in the disclosed content. The focus remains on organic growth and selective M&A opportunities mainly related to

Any current/future capex/capital investment/strategic investment?

Current expansion already incurred about 50%-60% of planned capex, mostly through internal sources with minimal loans (~Rs. 1 Cr utilized out of Rs. 2 Cr loan). Existing capacity can support sales up to Rs. 220-240 Cr without major new investment. Further capex for product registration and formulation expected in the next phase. Once sales reach Rs. 260-270 Cr, a new injectable manufacturing line (lyophilized) will be added; land and space available for 2-3 more blocks. Estimated investment for injectable line expansion is Rs. 30-35 Cr, funded mainly from reserves without significant new loans

Future growth expectations in sales/revenue/volumes?

The company targets a 30% to 35% annual growth rate in sales/revenue over the next 3 to 4 years. For FY22, the expected revenue is around Rs. 200 crore, with the second half projected to outperform the first half. The current capacity can support sales growth up to approximately Rs. 220 crore to Rs. 240 crore without major new CAPEX. Beyond Rs. 260-270 crore sales, a modest CAPEX of Rs. 30-35 crore is planned for new injectable production lines to sustain growth. International market expansion is underway, targeting 22 additional countries and focusing on Latin America, CIS, Southeast

Future growth expectations in earnings/operating earnings/profits/EPS?

Management expects EBITDA margin to improve by 100 to 150 basis points annually over the next 2-3 years (Page 10). The company targets 30% to 35% annual sales growth for the next 3-4 years, driven by branded formulations, exports, and API segments (Pages 5, 9, 10). Second half of the financial year is expected to be better than the first half, supporting earnings growth (Page 3). Margin expansion is supported by increased own branded formulations and export revenues (Pages 9, 10). Cost advantage due to in-house API development and focus on oncology products contribute to profitability (Page 3)

Current/ Expected Orderbook/ Pending Orders?

The company has a healthy order book with institutional orders lined up, contributing to expected robust growth in the current financial year (Page 7). Orders from corporate hospitals and private markets are increasing steadily, supporting sales growth in branded formulations (Page 7-8). Exports registrations are underway with regulatory filings and inspections expected soon, which will further strengthen order inflows from export markets (Page 5, 13). CRAM (Contract Research and Manufacturing) business has steady long-term customer relationships with recurring annual agreements and no reporte

Beta Drugs LtdQ2 FY22Pharmaceuticals & Biotechnology

Beta Drugs Ltd Q2 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,849.7P/E: 45.0Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company targets a 30% to 35% annual growth rate in sales/revenue over the next 3 to 4 years.
For FY22, the expected revenue is around Rs. 200 crore, with the second half projected to outperform the first half.
The current capacity can support sales growth up to approximately Rs. 220 crore to Rs. 240 crore without major new CAPEX.
Beyond Rs. 260-270 crore sales, a modest CAPEX of Rs. 30-35 crore is planned for new injectable production lines to sustain growth.
International market expansion is underway, targeting 22 additional countries and focusing on Latin America, CIS, Southeast Asia, and Africa, with substantial growth expected from 2023 onwards.
The company plans to launch 20-25 molecules in upcoming years, with emphasis on oncology segments like hematology, lung, breast, and prostate cancers, driving future volume increases.
Export revenue is expected to contribute 30-35%, alongside growing domestic branded sales.

Margin guidance

Category 3

Management expects EBITDA margin to improve by 100 to 150 basis points annually over the next 2-3 years (Page 10).
The company targets 30% to 35% annual sales growth for the next 3-4 years, driven by branded formulations, exports, and API segments (Pages 5, 9, 10).
Second half of the financial year is expected to be better than the first half, supporting earnings growth (Page 3).
Margin expansion is supported by increased own branded formulations and export revenues (Pages 9, 10).
Cost advantage due to in-house API development and focus on oncology products contribute to profitability (Page 3).
EBITDA margin expansion and revenue growth together indicate strong outlook for operating earnings and profits.

See what Beta Drugs Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Current expansions have been mostly funded through internal sources; out of Rs. 78 crore invested in three companies, only Rs. 1 crore has been utilized out of a Rs. 2 crore loan.
The company aims to avoid taking substantial new loans and has enough reserves for planned expansions.
Future CAPEX for injectable line expansion (estimated Rs. 30-35 crore) will be met without major debt, maintaining the company’s current financial status.
No explicit mention of planned equity fundraising in the disclosed content.
The focus remains on organic growth and selective M&A opportunities mainly related to Oncology, but no clear plans for fundraising through equity or debt were discussed.

Order book

The company has a healthy order book with institutional orders lined up, contributing to expected robust growth in the current financial year (Page 7).
Orders from corporate hospitals and private markets are increasing steadily, supporting sales growth in branded formulations (Page 7-8).
Exports registrations are underway with regulatory filings and inspections expected soon, which will further strengthen order inflows from export markets (Page 5, 13).
CRAM (Contract Research and Manufacturing) business has steady long-term customer relationships with recurring annual agreements and no reported order cancellations (Page 9).
Expansion plans are linked to capacity utilization, with new production lines and blocks being added to meet rising demand and to onboard new orders (Pages 14-15).
Overall, order book is set to support a targeted 30%-35% growth annually over the next few years (Page 5, 9).

See what Beta Drugs Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Current expansion already incurred about 50%-60% of planned capex, mostly through internal sources with minimal loans (~Rs. 1 Cr utilized out of Rs. 2 Cr loan).
Existing capacity can support sales up to Rs. 220-240 Cr without major new investment.
Further capex for product registration and formulation expected in the next phase.
Once sales reach Rs. 260-270 Cr, a new injectable manufacturing line (lyophilized) will be added; land and space available for 2-3 more blocks.
Estimated investment for injectable line expansion is Rs. 30-35 Cr, funded mainly from reserves without significant new loans.
Discussions underway for regulated market expansions, including EU market entry via MA acquisition.
M&A strategy focused on opportunities linked to Oncology divisions; engagement with Deloitte and pharma-specific contacts to explore acquisitions.
R&D capex increasing towards product development, aiming for 5-7 new molecule developments per year.

Track Beta Drugs Ltd — get its next earnings analysis in your feed

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBeta Drugs Ltd

Rev 2Mar 3

See where Beta Drugs Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Beta Drugs Ltd rank in Pharmaceuticals & Biotechnology?

Compare Beta Drugs Ltd against every Pharmaceuticals & Biotechnology company (Q2 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Beta Drugs Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →